drugset / Trial / NCT04159766
A Study With NLY01 in Subjects With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2 diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic effects on glycemic control.
Timeline
- Start
- 2019-10-16
- Primary completion
- 2020-12-04
- Completion
- 2020-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NLY01 | Peptide | 2.5 mg | — |
| Comparator | NLY01 | Peptide | 5 mg | — |
| Comparator | NLY01 | Peptide | 10 mg | — |